Cell line to investigate buccal mucosa, and as a model for absorption and metabolism of various substances and enzymatically labile drugs.
| Inventor | Institute |
|---|---|
| Bridget Hill | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151425 |
|---|---|
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Head and neck cancer |
| Research Fields: | Cancer;Drug development;Metabolism |
| Organism: | Human |
| Tissue: | Buccal mucosa that had infiltrated a lymph node |
| Gender: | Female |
| Model: | Tumourigenic cell line |
| Growth properties: | Adherent |
| Cancer Types In Detail: | Human neck metastasis |
| Primary citation: | Rupniak et al. 1985. J Natl Cancer Inst. 75(4):621-35. PMID: 2413234 |
| Alternate name: | Tr146; TR-146; TR 146 |
|---|---|
| Product description: | Derived from well-differentiated keratinising squamous cell carcinoma of the buccal mucosa the TR146 cell line represents an in vitro model to study permeability, absorption and metabolism of various enzymatically labile drugs and substances including epithelial-mesenchymal transition (EMT) markers, tight junction proteins and aquaporins. Due to morphological similarities and comparable permeability, excised porcine buccal mucosa has been considered a reasonably good model of human buccal mucosa for drug delivery studies. However, for rapid and efficient screening of drug permeability, a cell line generally holds advantages over in vitro models of excised tissue. Closely resembling normal human buccal epithelium, the cell line functions as a reliable oral mucosa model. TR146 has been characterised for permeability of a number of substances of varying molecular weight and hydrophilicity over a range of pH and osmolarity. Activity of aminopeptidase, carboxypeptidase and esterase has also been studied and shown to be comparable with that of human buccal epithelium. |
| Conditional: | Yes |
| CRISPR: | No |
| Production details: | The TR146 cell line originates from a human neck metastasis of a buccal carcinoma, derived from neck node (primary tumour sited in buccal mucosa). Well-differentiated. Female patient, 67 years. Previous radiotherapy (6,000 rads) and neck dissection |
| Additional notes: | Histology: well-differentiated keratinizing squamous cell carcinoma. Cell type: polygonal |
| Cellosaurus ID: | CVCL_2736 |
| Model description: | TR146 cell ine is tumourigenic in female (nu/nu) mice resulting in the production of rapidly progressing tumours |
| disease: | Cancer |
| Gender: | Female |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | HAMS F12 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS) |
| Subculture routine: | Split sub-confluent cultures (70-80%) seeding at approximately 1-2 x 10^4 cells/cm2 using 0.05% trypsin or trypsin/EDTA; 5% CO2; 37°C. Cells can reach a maximum density of 7 x 10^4 cells/cm2. Please also see detailed protocol within the Product Datasheet in the Documentation section below. |
| Temperature: | 37°C |
| Atmosphere: | 5% CO2 |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Lin et. al. 2021. Pharmaceutics 13(2):256. PMID: 33673378 Mogavero and Hube. 2021. Methods Mol Biol 2260:133-143. PMID: 33405035 Lin et. al. 2020. Tissue Barriers 8(2): 1784644. PMID: 32614652 Rupel et.al. 2019. NPJ Biofilms Microbiomes. 5: 29. PMID: 31602310 Laurén et.al. 2018. Pharm Res. 22,35(7):145. PMID 29790010 Kalu et al. 2017. Oncotarget. 8(49):86369-86383. PMID: 29156801 Li et al. 2017. Cancer Cell. 31(2):225-239. PMID: 28196595 Pistone et al. 2016. Eur J Pharm Sci. 96:381-389. PMID: 27721043 Nilsen et al. 2016. Eur J Oral Sci. :. PMID: 27711994 Iyire et al. 2016. Sci Rep. 6:32498. PMID: 27581177 Goyer et al. 2016. PLoS One. 11(3):e0149159. PMID: 26933885 Hyakusoku et al. 2016. J Exp Clin Cancer Res. 35:6. PMID: 26754630 Zeng et al. 2015. Int J Pharm. 495(2):1028-37. PMID: 26403384 De Ryck et al. 2015. AMB Express. 5:27. PMID: 25995981 O'Callaghan et al. 2015. Mol Med Rep. :. PMID: 26005189 Chai et al. 2012. J R Soc Interface. 9(77):3528-38. PMID: 22915635 Mrck Nielsen et al. 2000. Int J Pharm. 200(2):261-70. PMID: 10867256 Nielsen et al. 2000. Int J Pharm. 194(2):155-67. PMID: 10692640 Jacobsen et al. 1999. Eur J Pharm Biopharm. 48(3):217-24. PMID: 10612032 Nielsen et al. 1999. Int J Pharm. 185(2):215-25. PMID: 10460917 Nielsen et al. 1999. J Control Release. 60(2-3):223-33. PMID: 10425328 Pedersen et al. 1999. Drug Dev Ind Pharm. 25(4):463-70. PMID: 10194601 Jacobsen et al. 1999. Eur J Oral Sci. 107(2):138-46. PMID: 10232463 Rupniak et al. 1985. J Natl Cancer Inst. 75(4):621-35. PMID: 2413234 |
|---|
| Cat. # | Tool Name | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151447 | CMT 64 Cell Line |
Key Info
CMT 64 Cell Line
|
View Tool | |||||||||||||
| 151463 | Omega-E Packaging Cell Line |
Key Info
Omega-E Packaging Cell Line
|
View Tool | |||||||||||||
| 151480 | HEK293A EGFP-LC3 Cell Line |
Key Info
HEK293A EGFP-LC3 Cell Line
|
View Tool | |||||||||||||
| 151655 | FLYA-13 Cell Line |
Key Info
FLYA-13 Cell Line
|
View Tool | |||||||||||||
| 151672 | PEO1 Cell Line |
Key Info
PEO1 Cell Line
|
View Tool | |||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.